Smartlab Europe

Russia approves Sputnik V Covid-19 vaccination with flu shot

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Cosentyx Secures FDA Approval for Paediatric HS Treatment

Novartis has received approval from the US Food and...

Online Medicine in India: Where Ganaton Total Fits in Modern Digestive Care

The demand for online medicine delivery in India has...

How Advanced Imaging and Digital Diagnostics Are Improving Patient Outcomes

Advancements in medical imaging and digital diagnostic technologies are...
- Advertisement -

The Health Ministry of Russia has reportedly granted approval for administering Covid-19 vaccine Sputnik V and flu shots simultaneously, making changes to the instruction for the vaccine use.

Studies have demonstrated that the joint administration of both vaccines has not reduced their effectiveness.

Russian news agency TASS quoted Health Ministry as saying in a statement: “The combination of Sputnik V with the influenza vaccine has been studied in preclinical trials, showing no decrease in immunogenicity of both vaccines when they are administered simultaneously.

“When Covid-19 and flu vaccines are administered simultaneously, the shots are injected to different parts of the body, for example, the left and right shoulders.”

The Gamaleya National Research Institute of Epidemiology and Microbiology has developed the Sputnik V vaccine based on a human adenovirus vector platform.

The vaccine uses two different human adenoviral vectors to enhance the immune response and provide immunity that lasts long. It secured approval for use in 70 countries globally.

Recently, the World Health Organization (WHO) has kept Sputnik V’s Emergency Use Listing (EUL) process, on hold due to pending legal procedures and missing data.

WHO assistant director-general for access to medicines and health products Mariangela Simao stated that the vaccine’s case will be reopened and the submitted data will be evaluated even though it is not complete, only after reaching an agreement.

Simao further added that inspections of manufacturing sites in Russia will resume.

The Russian Direct Investment Fund and Gamaleya have also announced that the one-shot Sputnik Light vaccine demonstrated an effectiveness of 70% against the Delta variant of the virus following three months of vaccination.

Latest stories

Related stories

Cosentyx Secures FDA Approval for Paediatric HS Treatment

Novartis has received approval from the US Food and...

Online Medicine in India: Where Ganaton Total Fits in Modern Digestive Care

The demand for online medicine delivery in India has...

How Advanced Imaging and Digital Diagnostics Are Improving Patient Outcomes

Advancements in medical imaging and digital diagnostic technologies are...

A Guide to Exploring the Right Cancer Medication

Research and development efforts for making more effective cancer...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »